三谷誠一郎

ミタニセイイチロウ | Mitani Seiichiro

所属機関・部署：
論文 (61件)：

Yosuke Kito, Hisato Kawakami, Seiichiro Mitani, Shinichi Nishina, Toshihiko Matsumoto, Takao Tsuzuki, Yudai Shinohara, Hozumi Shimokawa, Ryosuke Kumanishi, Takashi Ohta, et al. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). The oncologist. 2024. 29. 3. e330-e336
Seiichiro Mitani, Yosuke Kito, Kaori Hino, Kentaro Kawakami, Naoki Izawa, Fumiyasu Hanamura, Yoshiyuki Yamamoto, Hirokazu Shoji, Azusa Komori, Shogen Boku, et al. Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study. Targeted oncology. 2023. 18. 5. 707-715
Ryosuke Kumanishi, Shigenori Kadowaki, Seiichiro Mitani, Tomohiro Matsushima, Takatsugu Ogata, Yukiya Narita, Toshiki Masuishi, Hideaki Bando, Masahiro Tajika, Hisateru Yasui, et al. Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study. International journal of clinical oncology. 2023. 28. 6. 756-763
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, et al. Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society. 2023. 20. 2. 290-290
Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, Hiroaki Kanemura, Seiichiro Mitani, Kaoru Tanaka, Hisato Kawakami, Yo Kishimoto, Yasuharu Haku, Katsuhiro Ito, et al. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. Frontiers in immunology. 2023. 14. 1325462-1325462

MISC (17件)：

佐藤千尋, 三谷誠一郎, 川上尚人. 【新しい抗体薬;ADC】消化器がんに対するADC. がん分子標的治療. 2019. 17. 2. 133-138
三谷誠一郎, 門脇重憲, 舛石俊樹, 谷口浩也, 宇良敬, 安藤正志, 田近正洋, 古平毅, 安部哲也, 室圭. 切除不能進行食道扁平上皮癌に対するmodified FOLFOX6療法の検討. 日本食道学会学術集会プログラム・抄録集. 2018. 72回. 393-393
加藤恭子, 成田有季哉, 三谷誠一郎, 本多和典, 舛石俊樹, 谷口浩也, 門脇重憲, 宇良敬, 安藤正志, 田近正洋, et al. 抗PD-(L)1抗体薬不応後の切除不能胃癌に対する化学療法の有効性(Efficacy of chemotherapy after progression on anti-PD-(L)1 antibody for metastatic gastric cancer). 日本胃癌学会総会記事. 2018. 90回. 485-485
Naoki Fukuda, Sadayuki Kawai, Katsuhiro Omae, Seiichiro Mitani, Takeru Wakatsuki, Ken Kato, Shigenori Kadowaki, Daisuke Takahari, Narikazu Boku, Kei Muro, et al. Retrospective observational study of salvage line ramucirumab monotherapy (RAM) for patients (pts) with unresectable advanced gastric cancer (AGC) which was refractory to fluoropyrimidine and taxanes. JOURNAL OF CLINICAL ONCOLOGY. 2018. 36. 4
谷口浩也, 三谷誠一郎, 室圭. 大腸がん化学療法の最前線切除不能BRAF変異型大腸がんに対する治療戦略. 日本消化管学会雑誌. 2018. 2. Suppl. 199-199

学位 (1件)：

医学部博士 (近畿大学)

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

三谷 誠一郎

三谷誠一郎